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Index (CDAI), SF-36, and EQ-5D. “Best” health was identiﬁed
by CDAI scores < median, SF-36 Physical and Mental Compo-
nent Scores (PCS and MCS) ≥ median, and modality “1”
responses to the EQ-5D dimensions. The non-parametric
Wilcoxon test was used to compare the WPAI : CD scores
between the subgroups. RESULTS: CD patients with the “worst”
disease severity (CDAI > 288.1) showed higher impairment in
work (+8.9%) and activities (+10.0%) vs. patients with “best”
health. Similarly patients with “worst” HRQoL, as demon-
strated by SF-36 PCS < 37.5 and MCS < 37.4, showed higher
impairments in work (+20.0% by PCS, +18.5% by MCS) and
activities (+22.2% by PCS, +15.5% by MCS) vs. “best” HRQoL.
Patients with the “worst” EQ-5D states reported more impair-
ment in work (+15.2% averaged over the 5 dimensions) and
activities (+17.3%) vs. patients with the “best” states. All 
p-values were <0.001. CONCLUSION: The measurement of
expected differences in work and activity impairment by disease
severity and HRQoL levels supports the discriminant validity of
the WPAI : CD.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD) inter-
feres with work productivity through two main mechanisms.
Nighttime symptoms disturb sleep and cause daytime tiredness,
while daytime symptoms affect work productivity by interrupt-
ing physical and social activities. A recent systematic review
using data in general working populations from three separate
studies indicated that GERD causes a reduction in productivity
while at work of around 10%. The level of work productivity is
strongly associated with symptom severity, symptom frequency,
and the occurrence of nighttime symptoms. Hence, levels con-
siderably higher than 10% have been observed in untreated
patients with troublesome symptoms, e.g. up to 40% in patients
with GERD-related sleep disturbances. The objective of this
study was to estimate the effects of GERD on productivity while
at work in France. METHODS: Work productivity data from
two international studies in general working populations (n =
1111 and 1516, respectively) were used to compare results from
the French sub-populations with overall results. Based on the
results of these French sub-populations, estimation was made 
of the total work time lost because of GERD-related reduced
work productivity. RESULTS: Findings from the French sub-
populations were consistent with overall ﬁndings from the total
samples, which indicated that GERD causes an average reduc-
tion in at-work productivity of around 10%. Assuming a French
population of 36 million in working age, a prevalence of diag-
nosed GERD of approximately 10% and that 63% of GERD
patients are employed and work around 36 hours per week, then
it can be estimated that GERD causes an at-work productivity
loss corresponding to around 380 million work hours per year
in France. CONCLUSIONS: Intermediated through reduced
productivity while at work, GERD symptoms have implications
well beyond the individual patient perspective in terms of
number of work hours lost for the French community.
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OBJECTIVES: To explore the association between work pro-
ductivity and response to treatment with proton pump inhibitors
(PPIs) in patients with gastroesophageal reﬂux disease (GERD).
METHODS: Interviews were conducted with 1908 patients with
symptoms of GERD in the USA, UK, Germany and France.
Patients diagnosed with GERD who were receiving PPIs were
classiﬁed as complete responders (no symptoms), well-controlled
(used a PPI compliantly, experienced an improvement in or
decrease in frequency of symptoms, and suffered key GERD
symptoms on ≤1 of the past seven days), incomplete responders
(the same deﬁnition as well-controlled but with symptoms on ≥2
of the past seven days), or non-responders (no improvement or
symptoms worsened). Information obtained included GERD-
related absence from work and reduced productivity while at
work because of GERD during the past seven days. RESULTS:
The analysis included 237 employed patients on PPI treatment.
The mean number of hours absent from work because of GERD
was 0.1 for complete responders (n = 57), 0.1 for well-controlled
(n = 32), 0.5 for incomplete responders (n = 128), and 1.3 for
non-responders (n = 20). The mean percentage reduced produc-
tivity while at work was 4.3% for complete responders, 7.8%
for well-controlled, 14.9% for incomplete responders, and
17.6% for non-responders. When pooling results for complete
responders and well-controlled vs. incomplete responders and
non-responders, mean differences between these two groups
were 0.5 hours absence (0.1 vs. 0.6, p < 0.05) and a 9.7% reduc-
tion in work productivity (5.6% vs. 15.3%, p < 0.0001). The
9.7% difference in reduced productivity while at work corre-
sponds to an equivalent of 3.9 work hours lost (% reduced pro-
ductivity x hours worked) per patient, based on a 40-hour
working week. CONCLUSIONS: There are signiﬁcant differ-
ences in GERD-related work productivity depending on response
to medical treatment, which suggests that strategies for improv-
ing management of GERD may be warranted.
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OBJECTIVES: To explore cost-effectiveness of prophylaxis with
Refacto® (B-domain-deleted recombinant FVIII) in adults with
hemophilia A. METHODS: A prospective, open, uncontrolled
study was designed. Patients with hemophilia A aged 18 years
or more, with frequent bleeding episodes, switching from on-
demand treatment (ODT) to prophylaxis (PT), have been
enrolled. All patients were treated with 25 IU/Kg of Refacto® 3
times-a-week for all the 6-month study period. Bleeding event
rate and FVIII concentrate consumption have been evaluated
over on-demand treatment time period (ODP), 6 months before
enrolment, and the prophylaxis time period (PP), 6 months after
enrolment. Medical costs (that represent 99% of total costs) have
